# PSMB9

Source: https://onco.cc/targets/psmb9/  
OnCo record `psmb9` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMB9 (Proteasome subunit beta type-9) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.

## Summary

The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 20S subunit beta 9; Proteasome subunit beta type-9; RING12; beta1i; PSMB6i; LMP2
- Tags: cancer-genes-wave
- Symbol: PSMB9
- Class: enzyme
- Biology: The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.32 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693); Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9546: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9546
- UniProt P28065: https://www.uniprot.org/uniprotkb/P28065/entry
- NCBI Gene 5698: https://www.ncbi.nlm.nih.gov/gene/5698
- Ensembl ENSG00000240065: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240065

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmb9.json